HealthStream Narrows FY2025 Sales Guidance from $297.500M-$303.500M to $299.500M-$301.500M vs $299.965M Est
Benzinga Newsdesk 12 months ago
NewsGuidance
Financial Outlook for 2025The Company is updating its guidance for 2025 for the measures set forth below. For a reconciliation of projected adjusted EBITDA, a non-GAAP financial measure defined later in this release, to
Financial Outlook for 2025
The Company is updating its guidance for 2025 for the measures set forth below. For a reconciliation of projected adjusted EBITDA, a non-GAAP financial measure defined later in this release, to projected net income (the most comparable GAAP measure) for 2025, see the table included on page nine of this release.
| Full Year 2025 Guidance | ||||||||||
| Low | High | |||||||||
| Revenue1 | $ | 299.5 | - | $ | 301.5 | million | ||||
| Net Income2 | $ | 20.3 | - | $ | 21.5 | million | ||||
| Adjusted EBITDA3 | $ | 69.5 | - | $ | 71.5 | million | ||||
| Capital Expenditures4 | $ | 33.0 | - | $ | 34.0 | million | ||||
| 1 Previous expected Revenue guidance range was $297.5 to $303.5 million. | ||||||||||
| 2 Previous expected Net Income guidance range was $19.5 to $22.4 million. | ||||||||||
| 3 Previous expected Adjusted EBITDA guidance range was $68.5 to $72.5 million. | ||||||||||
| 4 Previous expected Capital Expenditures guidance range was $32.0 to $34.0 million. | ||||||||||
The Company's guidance for 2025, as set forth above, reflects the Company's assumptions regarding, among other things, expectations for new sales and renewals. This guidance does not include the impact of any future acquisitions or dispositions that we may complete during 2025, gains or losses from changes in the fair value of non-marketable equity investments, or impairment of long-lived assets.